Abstract
The low efficacy of treatment and high rates of bladder cancer (BC) recurrence may be related to the low effects of these therapies on the mechanisms of tissue repair, angiogenesis, and reactive oxygen species (ROS). Furthermore, current drugs have low residence time and low penetration in the urothelium, contributing to the reduction of therapeutic response. Nowadays, the most effective …